MediGene AG

euro adhoc: MediGene AG
MediGene and Yamanouchi Conclude Marketing and Development Partnership For Anti-Cancer Drug Leuprogel® (New Name: Eligard®) (E)

--------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. --------------------------------------------------------------------- Martinsried - San Diego, January 14, 2004. The German-American biotechnology company MediGene AG (Frankfurt, Prime Standard: MDG) has concluded a partnership with the pharmaceuticals group Yamanouchi for the commercialization in Europe of the anti-cancer drug Eligard®, previously known as Leuprogel®. Yamanouchi, the second largest pharmaceuticals company in Europe in the field of urology, will take on pan-European promotion and sale of the drug for the treatment of prostate cancer. In return MediGene will receive successive milestone payments totaling up to EUR23.5 million including a signing fee of EUR4 million, as well as royalties on sales of Eligard®. At the beginning of December 2003, the one-month sustained release product of Leuprogel® / Eligard® received marketing authorization for Germany. The three-months product is still undergoing approval procedure by the German regulatory authorities. In April 2001, MediGene had acquired the license for Leuprogel® / Eligard® from the US company Atrix Laboratories, Inc. Contact: MediGene AG, e-mail: investor@medigene.com, Fax: ++ 49 - 89 - 85 65 - 2920 Julia Hofmann, Public Relations , Phone: ++ 49 - 89 - 85 65 - 3324 Dr. Michael Nettersheim, Investor Relations, Phone: ++ 49 - 89 - 85 65 - 2946 end of announcement euro adhoc 14.01.2004 --------------------------------------------------------------------- Further inquiry note: Julia Hofmann Tel.: +49 (0)89 8565 3324 E-Mail: j.hofmann@medigene.com Branche: Biotechnology ISIN: DE0005020903 WKN: 502090 Index: CDAX, Prime All Share, Prime Standard, Technologie All Share Börsen: Frankfurter Wertpapierbörse / regulated dealing Niedersächsische Börse zu Hannover / free trade Berliner Wertpapierbörse / free trade Bayerische Börse / free trade Hamburger Wertpapierbörse / free trade Bremer Wertpapierbörse (BWB) / free trade Börse Düsseldorf / free trade Baden-Württembergische Wertpapierbörse / free trade

Das könnte Sie auch interessieren: